Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030
Revenue and EPS summary
| H1 2026 | % Change | Q2 2026 | % Change | |||
| $m | Actual | CER1 | $m | Actual | CER | |
| – Product Sales | 28,896 | 8 | 5 | 14,510 | 5 | 4 |
| – Alliance Revenue | 1,699 | 31 | 29 | 874 | 34 | 33 |
| Product Revenue | 30,595 | 9 | 6 | 15,384 | 6 | 5 |
| Collaboration Revenue | 77 | (6) | (9) | – | n/m | n/m |
| Total Revenue | 30,672 | 9 | 6 | 15,384 | 6 | 5 |
| Reported EPS ($) | 3.60 | 4 | 3 | 1.61 | 2 | (2) |
| Core2 EPS ($) | 5.21 | 12 | 11 | 2.63 | 21 | 18 |
Key performance elements for H1 2026
(Growth numbers at constant exchange rates)
* Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from Farxiga US loss of exclusivity and China volume-based procurement
* Core Operating profit and Core EPS increased 11%
* Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK)
* 30 approvals in major regions since Q4 2025 results
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
“In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension.
While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months.
We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030.”
Guidance
AstraZeneca reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign exchange rates through 2025.
Total Revenue is expected to increase by a mid-to–high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage
The Core Tax rate is expected to be between 18-22%
If foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER.
http://www.rns-pdf.londonstockexchange.com/rns/9440N_1-2026-7-26.pdf
Notes
1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
2. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document.
3. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement.